GLP-1 receptor agonists stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning they only promote insulin release when blood glucose levels are elevated
Treatment should be discontinued if less than 5% of body weight is lost after 3 months
Rapid weight loss, reduced appetite, and altered nutrient intake can negatively affect bone density a particular concern for women who already face hypoestrogenic states from certain endometriosis treatments
What the courts decide in this matter will affect the future of many plaintiffs in the Trulicity litigation
Alcohol is not formally contraindicated with semaglutide or tirzepatide, but clinical guidance advises caution because both affect the stomach, blood sugar, and hydration through overlapping pathways
Its no secret that GLP-1 drugs like Ozempic and Wegovy are dominating headlines and prescriptions